Summary
Vertex Pharmaceuticals Incorporated's (VRTX) 2018 10-K filing highlights a year of significant growth driven by its cystic fibrosis (CF) franchise. The company's core CF medicines – KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI – are now approved for approximately half of the estimated 75,000 CF patients in North America, Europe, and Australia. A key focus for investors is Vertex's progress in developing next-generation triple combination therapies (VX-659 and VX-445 with tezacaftor and ivacaftor), which have the potential to treat approximately 90% of all CF patients. Positive Phase 3 data for the VX-659 combination was reported, and the company anticipates reporting data for the VX-445 combination in early 2019, with a potential New Drug Application (NDA) submission by mid-2019. Financially, Vertex reported substantial revenue growth, with total revenues increasing by 22% to $3.05 billion. Net income saw a dramatic rise to $2.10 billion, largely influenced by a significant one-time tax benefit from releasing a valuation allowance. The company maintained a strong balance sheet with $3.17 billion in cash, cash equivalents, and marketable securities as of year-end 2018. Beyond CF, Vertex is advancing pipeline programs in pain, sickle cell disease, beta-thalassemia, and alpha-1 antitrypsin deficiency, demonstrating a strategy to diversify its therapeutic focus.
Financial Highlights
53 data points| Revenue | $3.05B |
| Cost of Revenue | $409.54M |
| Gross Profit | $2.64B |
| R&D Expenses | $1.42B |
| SG&A Expenses | $557.62M |
| Operating Expenses | $2.41B |
| Operating Income | $635.15M |
| Interest Expense | $72.47M |
| Net Income | $2.10B |
| EPS (Basic) | $8.24 |
| EPS (Diluted) | $8.09 |
| Shares Outstanding (Basic) | 254.29M |
| Shares Outstanding (Diluted) | 259.19M |
Key Highlights
- 1Vertex's CF medicines (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) now cover approximately half of the estimated 75,000 CF patients in key markets, with significant revenue growth driven by SYMDEKO/SYMKEVI.
- 2Positive Phase 3 data for the VX-659 triple combination therapy has been announced, with an anticipated NDA submission for a triple combination regimen by mid-2019.
- 3Total revenues increased 22% to $3.05 billion in 2018, primarily driven by a 40% increase in CF product revenues.
- 4Net income surged to $2.10 billion, significantly boosted by a $1.56 billion one-time tax benefit related to the release of a valuation allowance.
- 5The company ended 2018 with a strong cash position of $3.17 billion, indicating financial flexibility for R&D and business development.
- 6Vertex is actively expanding its pipeline beyond CF, with promising early-stage development in pain (VX-150), sickle cell disease/beta-thalassemia (CTX001 via collaboration with CRISPR Therapeutics), and alpha-1 antitrypsin deficiency.